PE20200956A1 - Antagonistas de ildr2 y combinaciones de los mismos - Google Patents

Antagonistas de ildr2 y combinaciones de los mismos

Info

Publication number
PE20200956A1
PE20200956A1 PE2020000620A PE2020000620A PE20200956A1 PE 20200956 A1 PE20200956 A1 PE 20200956A1 PE 2020000620 A PE2020000620 A PE 2020000620A PE 2020000620 A PE2020000620 A PE 2020000620A PE 20200956 A1 PE20200956 A1 PE 20200956A1
Authority
PE
Peru
Prior art keywords
ildr2
combinations
antagonists
ildr2 antagonists
new
Prior art date
Application number
PE2020000620A
Other languages
English (en)
Spanish (es)
Inventor
Lars Rose
Uwe Gritzan
Julia Hutter
Spencer Liang
Andrew Pow
John Hunter
Ofer Levy
Ilan Vaknin
Original Assignee
Bayer Ag
Bayer Pharma AG
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG, Compugen Ltd filed Critical Bayer Ag
Publication of PE20200956A1 publication Critical patent/PE20200956A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PE2020000620A 2017-11-30 2018-11-28 Antagonistas de ildr2 y combinaciones de los mismos PE20200956A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592913P 2017-11-30 2017-11-30
PCT/EP2018/082779 WO2019105972A1 (en) 2017-11-30 2018-11-28 Ildr2 antagonists and combinations thereof

Publications (1)

Publication Number Publication Date
PE20200956A1 true PE20200956A1 (es) 2020-09-24

Family

ID=64559680

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000620A PE20200956A1 (es) 2017-11-30 2018-11-28 Antagonistas de ildr2 y combinaciones de los mismos

Country Status (16)

Country Link
US (1) US11655297B2 (enExample)
EP (1) EP3717007B1 (enExample)
JP (1) JP7350740B2 (enExample)
KR (1) KR20200096223A (enExample)
CN (1) CN111655287B (enExample)
AR (1) AR113850A1 (enExample)
AU (1) AU2018376231A1 (enExample)
BR (1) BR112020010767A2 (enExample)
CA (1) CA3083675A1 (enExample)
IL (1) IL274751B2 (enExample)
MX (1) MX2020005483A (enExample)
PE (1) PE20200956A1 (enExample)
RU (1) RU2020121533A (enExample)
SG (1) SG11202003323TA (enExample)
TW (1) TW201934119A (enExample)
WO (1) WO2019105972A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3952910A1 (en) * 2019-04-11 2022-02-16 Bayer Aktiengesellschaft Combinations of anti-ildr2 antibodies and pd-1 antagonists
CN111574626B (zh) * 2020-05-27 2021-12-31 斯爱玲 一种ildr2抗体、其药物组合物及其用途
CN111558038B (zh) * 2020-05-27 2022-04-19 北京加美康联健康管理集团有限公司 一种用于癌症治疗的免疫检查点抑制剂
IL301396A (en) 2020-09-30 2023-05-01 Nobell Foods Inc Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP2769729B1 (en) 2007-09-04 2019-01-09 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US20130209463A1 (en) * 2010-06-30 2013-08-15 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
AU2012277376B2 (en) * 2011-06-30 2016-11-24 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
JP2015512616A (ja) * 2012-02-01 2015-04-30 コンピュゲン エルティーディー． Ｃ１ｏｒｆ３２抗体およびがんの治療のためのその使用
US20170233473A1 (en) * 2014-05-27 2017-08-17 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
PT3789042T (pt) 2014-04-10 2025-01-14 Daiichi Sankyo Europe Gmbh Método para produzir conjugado anticorpo-fármaco anti-her3
AU2016323582B2 (en) 2015-09-16 2022-09-15 Ablexis, Llc Anti-CD115 antibodies

Also Published As

Publication number Publication date
MX2020005483A (es) 2020-08-27
EP3717007A1 (en) 2020-10-07
KR20200096223A (ko) 2020-08-11
CN111655287A (zh) 2020-09-11
AR113850A1 (es) 2020-06-17
AU2018376231A1 (en) 2020-05-07
CN111655287B (zh) 2024-12-27
IL274751B1 (en) 2024-07-01
TW201934119A (zh) 2019-09-01
WO2019105972A1 (en) 2019-06-06
EP3717007B1 (en) 2025-09-17
IL274751A (en) 2020-07-30
US20200369769A1 (en) 2020-11-26
EP3717007C0 (en) 2025-09-17
JP7350740B2 (ja) 2023-09-26
IL274751B2 (en) 2024-11-01
BR112020010767A2 (pt) 2020-11-24
SG11202003323TA (en) 2020-05-28
US11655297B2 (en) 2023-05-23
JP2021504404A (ja) 2021-02-15
CA3083675A1 (en) 2019-06-06
RU2020121533A (ru) 2021-12-30

Similar Documents

Publication Publication Date Title
PE20200956A1 (es) Antagonistas de ildr2 y combinaciones de los mismos
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
CO2017002532A2 (es) Indazoles sustituidos con bencilo como inhibidores de bub1
CL2017003486A1 (es) Lactamas bicíclicas y métodos de uso de las mismas
MX2017001512A (es) Compuestos activos hacia bromodominios.
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
CO2019005059A2 (es) Inhibidores de magl
CO2019005038A2 (es) Inhibidores de magl
CO2017002160A2 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
BR112016025910A2 (pt) uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
UY37410A (es) Antagonistas de trpv4
EP3817583A4 (en) AEROSOL GENERATION DEVICE
DE112020001082A5 (de) Löschvorrichtung
EP3731832A4 (en) CANNABINOID DOSAGE FORM
DK3749669T6 (da) Ahr-modulatorer
EP4346717A4 (en) INTRAVAGINAL RING DEVICES
EP3630113A4 (en) PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR
EP3942995A4 (en) SLIT LAMP MICROSCOPE
EP3976001A4 (en) APREMILAST TABLET FORMULATIONS
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
IL285765A (en) Therapeutic uses of dulaglutide
DK3649688T3 (da) Dobbeltaktive katodematerialer
EP4037505C0 (en) AEROSOL GENERATION DEVICES
EP3795166A4 (en) PHARMACEUTICAL COMPOSITION OF KOR RECEPTOR AGONIST
EP3847985C0 (en) SET OF SURGICAL ELECTRODES